Deep TMS for Methamphetamine Addiction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether deep transcranial magnetic stimulation (dTMS) can assist Veterans struggling with methamphetamine addiction. Participants will receive either the actual dTMS treatment or a sham version to compare results. Veterans with moderate to severe methamphetamine use disorder who can commit to frequent clinic visits may be suitable candidates. The goal is to determine if dTMS can reduce methamphetamine use and enhance overall well-being. As an unphased trial, this study offers Veterans the chance to contribute to groundbreaking research that could lead to new treatment options for methamphetamine addiction.
Will I have to stop taking my current medications?
If you are on a stable medication regimen for other symptoms, you can continue taking those medications during the study. However, you must stop taking any medications that increase seizure risk at least two weeks before starting the treatment.
What prior data suggests that deep transcranial magnetic stimulation (dTMS) is safe for treating methamphetamine use disorder?
Research has shown that deep transcranial magnetic stimulation (dTMS) is generally safe for people with methamphetamine use disorder (MUD). Several studies have used dTMS safely, reporting only a few minor side effects. These side effects are usually mild, such as headaches or scalp discomfort, and they typically resolve on their own.
Overall, past research considers dTMS a safe option for those with MUD. While no treatment is completely without risk, dTMS has demonstrated a low rate of serious side effects. This makes it a promising choice for those considering participation in trials for methamphetamine addiction.12345Why are researchers excited about this trial?
Researchers are excited about Deep Transcranial Magnetic Stimulation (dTMS) for methamphetamine addiction because it offers a non-invasive approach that directly targets brain regions involved in addiction. Unlike traditional treatments like behavioral therapy and medication, dTMS uses magnetic fields to modulate neural activity, potentially reducing cravings and improving self-control. This technique can be administered quickly, with each session lasting about 30 minutes, and it holds promise for delivering results over a short period, which is crucial for individuals struggling with addiction.
What evidence suggests that deep transcranial magnetic stimulation (dTMS) might be an effective treatment for methamphetamine addiction?
Research has shown that deep transcranial magnetic stimulation (dTMS) can help reduce drug cravings in people with methamphetamine addiction. In this trial, participants will join one of two groups: one receiving active dTMS and the other receiving sham dTMS. One study found that dTMS greatly improved self-control in those who had stopped using methamphetamine. Another review found that dTMS effectively lowered cravings and relapse rates. These findings suggest that dTMS may be a promising treatment for methamphetamine addiction by targeting specific brain areas linked to addiction.36789
Who Is on the Research Team?
Claudia B Padula, PhD
Principal Investigator
Stanford University
Michelle R Madore, PhD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
This trial is for veterans struggling with methamphetamine addiction. Participants should be seeking treatment and have no other major health issues that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 30 active or sham dTMS treatments, administered 3 times per day over 10 consecutive business days
Follow-up
Participants are monitored for methamphetamine use outcomes and salience network function
What Are the Treatments Tested in This Trial?
Interventions
- Deep Transcranial Magnetic Stimulation (dTMS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
VA Palo Alto Health Care System
Collaborator